Vision and Mission
Progressive multifocal leukoencephalopathy (PML) is a serious but rare (in the general population) infection of the central nervous system (CNS) which can and often does lead to severe disability or death. PML is caused by the simultaneous occurrence of a common virus known as JC virus combined with additional risk factors including a compromised immune system, use of certain prescription medications, and possibly genetic factors.
The PML Consortium is a joint multi-institution effort between Biogen Idec, Bristol-Myers Squibb, Elan Pharmaceuticals, Pfizer, MedImmune and Roche which is intended to enhance the understanding of, and to identify more effective methods of predicting, and eventually, preventing and treating PML. The Consortium was formed in 2009 out of a recognition of the importance of addressing PML and the benefits of a collaborative approach to obtain sufficient data and samples to conduct research to comprehensively evaluate the disease and identify new potential risk factors.
By pooling resources and sharing data, the Consortium hopes to make significant progress in understanding how to better minimize the risk of PML for patients, and to achieve the best care and protection for patients. To this end, the Consortium is undertaking a variety of research, clinical, regulatory and communications activities, and seeking collaborations with the scientific, medical, patient and regulatory communities.
The vision of the PML Consortium is to find methods to predict, prevent and treat PML associated with immunomodulatory and immunosuppressive treatments.
The mission of the Consortium is to perform research to reduce occurrence, morbidity and mortality of PML through a multi-company, not-for-profit, collaborative approach with shared strategy, investment, data acquisition and analysis and communication within a pre-defined scope and duration.